Navigation Links
New Findings Published In Circulation: Heart Failure Show Potential Utility Of Cardioxyl's HNO Donors As Novel Treatments For Heart Failure
Date:10/28/2013

CHAPEL HILL, N.C., Oct. 28, 2013 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today the publication of recent findings on the role of a novel pure nitroxyl (HNO) donor in enhancing cardiac function and hemodynamics. These findings, based upon analysis of preclinical and human clinical data from studies of CXL-1020, were published online October 9, 2013, in Circulation: Heart Failure, which is published by the American Heart Association.

"Patients with acute decompensated heart failure (ADHF) present with a complex and often life-threatening clinical syndrome – and new therapeutic advances remain scant. These published data demonstrate the functional improvement in myocardial performance produced by a novel pure HNO donor, and show first-in-human evidence for the potential utility of an HNO donor in heart failure," said Wilson "Bill" S. Colucci, M.D., Thomas J. Ryan Professor of Medicine and Chief of the Cardiovascular Medicine Section at Boston University Medical Center, who served as Chairman of the Steering Committee for the CXL-1020 Phase 2a clinical study.

The data published in Circulation: Heart Failure summarize study findings from two preclinical models as well as a clinical study examining the hemodynamic effects and safety of CXL-1020 at doses of 1–20 mg/kg/min in patients with advanced heart failure hospitalized for invasive hemodynamic monitoring. Investigators reported human data demonstrating that CXL-1020, a novel pure HNO donor, enhanced cardiac systolic function while reducing pulmonary capillary wedge pressure (PCWP) and arterial and venous tone without increasing heart rate. Consistent with the clinical data, direct contractile enhancement from CXL-1020 was observed in isolated myocytes as well as in vivo in experimental canine heart failure models. The investigators concluded that the combination of effects differentiates HNO donors from other classes of inotropes or ino-dilators, and provides a strong rationale for continuing studies to develop donors with optimized pharmacology for the treatment of congestive heart failure.

"Cardioxyl is excited about these results obtained with our first-generation HNO donor, and is poised to expand upon this data as we prepare to bring our second-generation HNO donor into the clinic next year," said Chris Kroeger, M.D., Cardioxyl's President and Chief Executive Officer.

The study is available online, via subscription, at http://circheartfailure.ahajournals.org/content/early/2013/10/09/CIRCHEARTFAILURE.113.000632

About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.


'/>"/>
SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ARUP Laboratories Presents Recent Findings at PAINWeek
2. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
3. Key Findings: Innovations in Ophthalmic Devices - Anterior Segment
4. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
5. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
6. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
7. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
8. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
9. Dr. Kevin Foley to Present DiscGenics Recent Findings at the Lumbar Spine Research Societys Annual Meeting
10. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
11. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
(Date:6/23/2016)... , June 23, 2016 ... "Surgical Procedure Volumes: Global Analysis (United States, China, ... Canada)" report to their offering. ... essential tool for healthcare business planners, provides surgical procedure ... at surgery trends with an in-depth analysis of growth ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
Breaking Medicine News(10 mins):